Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 3/20 | 0.43 |
| ▸ | F10 | P00742 | 3/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 2/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | SPR | P35270 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6015105 | 0.90 | VNN1 (0.46) | VNN1F10KDM5ACCR1ENPP2 | |
| SCHEMBL6015039 | 0.86 | VNN1 (0.47) | VNN1F10KDM5ACCR1ENPP2 | |
| SCHEMBL3449580 | 0.83 | F10 (0.39) | F10CCR1ENPP2MCHR1CNR2 | |
| SCHEMBL3449526 | 0.83 | CCR1 (0.36) | CCR1MCHR1SYKCNR2 | |
| SCHEMBL3450007 | 0.77 | CCR1 (0.33) | VNN1F10CCR1CNR2 | |
| SCHEMBL3449185 | 0.76 | CCR1 (0.34) | CCR1CNR2 | |
| SCHEMBL3448615 | 0.76 | CCR1 (0.33) | F10CCR1CNR2 | |
| SCHEMBL3452017 | 0.75 | L3MBTL3 (0.38) | F10CCR1 | |
| SCHEMBL19001333 | 0.74 | KDM5A (0.50) | VNN1F10KDM5AENPP2SPR | |
| SCHEMBL6015018 | 0.74 | CCR1 (0.41) | VNN1CCR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820673-B2 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | F2, URB2, F12 | VNN1 1496/4885F10 22/4885KDM5A 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.